var data={"title":"Rizatriptan: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rizatriptan: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6921?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rizatriptan-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rizatriptan: Patient drug information&quot;</a> and <a href=\"topic.htm?path=rizatriptan-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Rizatriptan: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218997\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Maxalt;</li>\n      <li>Maxalt-MLT</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218998\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Maxalt;</li>\n      <li>Maxalt RPD</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219026\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antimigraine Agent;</li>\n      <li>\n        Serotonin 5-HT<sub>1B, 1D</sub> Receptor Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219001\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In patients with risk factors for coronary artery disease, following adequate evaluation to establish the absence of coronary artery disease, the initial dose should be administered in a setting where response may be evaluated (physician's office or similarly staffed setting). ECG monitoring may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Migraine:</b> Oral: 5 to 10 mg, repeat after 2 hours if significant relief is not attained; maximum: 30 mg/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Dose adjustment with concomitant propranolol therapy:</i> 5 mg/dose (maximum: 15 mg/24 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292543\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=rizatriptan-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Rizatriptan: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In patients with risk factors for coronary artery disease, following adequate evaluation to establish the absence of coronary artery disease, the initial dose should be administered in a setting where response may be evaluated (physician's office or similarly staffed setting). ECG monitoring may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Migraine:</b> Oral: Children &ge;6 years and Adolescents: <b>Note:</b> Safety and efficacy of multiple rizatriptan doses in a 24-hour period have not been established for pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;40 kg: 5 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;40 kg: 10 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Dose adjustment with concomitant propranolol therapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;40 kg: Use not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;40 kg: 5 mg as a single dose (maximum: 5 mg/24 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219002\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292541\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, the AUC was 44% greater in patients on hemodialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292542\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, plasma concentrations are increased by 30% in patients with moderate hepatic dysfunction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218975\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maxalt: 5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maxalt-MLT: 5 mg [DSC] [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maxalt-MLT: 5 mg [contains aspartame; peppermint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maxalt-MLT: 10 mg [DSC] [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maxalt-MLT: 10 mg [contains aspartame; peppermint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218961\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14292544\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered with or without food. For orally-disintegrating tablets (Maxalt-MLT), patient should be instructed to place tablet on tongue and allow to dissolve. Dissolved tablet will be swallowed with saliva.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218976\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Migraine: </b>Acute treatment of migraine with or without aura</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218968\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (&le;3%), flushing (&gt;1%), palpitations (&gt;1%), flushing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (4% to 9%), drowsiness (4% to 8%), fatigue (adults: 4% to 7%; children: &gt;1%), paresthesia (3% to 4%), pain (3%), feeling of heaviness (&le;2%), headache (&le;2%), euphoria (&gt;1%), hypoesthesia (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (4% to 6%), xerostomia (3%), sore throat (&le;2%), abdominal distress (children: &gt;1%), diarrhea (&gt;1%), vomiting (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (4% to 7%), jaw pain (&le;2%), jaw pressure (&le;2%), jaw tightness (&le;2%), neck pain (&le;2%), neck pressure (&le;2%), neck tightness (&le;2%), tremor (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngeal edema (&le;2%), pressure on pharynx (&le;2%), dyspnea (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distention, abnormal gait, agitation, anaphylaxis, anaphylactoid reaction, angina pectoris, angioedema, ataxia (children), auditory impairment (children), blurred vision, bradycardia, cardiac arrhythmia, cold extremities, confusion, diaphoresis, dysgeusia, dyspepsia, edema, erythema, facial edema, hallucination (children), hot flash, hypertensive crisis, increased blood pressure (diastolic/systolic), insomnia, ischemic heart disease, lack of concentration (children), memory impairment, muscle rigidity, muscle spasm, myalgia, myocardial infarction, pharyngeal edema, pruritus, seizure, skin rash, swelling of eye, syncope, tachycardia, tinnitus, tongue edema, toxic epidermal necrolysis, urticaria, vasospasm, vertigo, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218980\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to rizatriptan or any component of the formulation; documented ischemic heart disease or other significant cardiovascular disease; coronary artery vasospasm (including Prinzmetal angina); history of stroke or transient ischemic attack; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; basilar or hemiplegic migraine; during or within 2 weeks of MAO inhibitors; during or within 24 hours of treatment with another 5-HT<sub>1</sub> agonist, or an ergot-containing or ergot-type medication (eg, methysergide, dihydroergotamine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Ophthalmoplegic migraine; severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218965\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT<sub>1</sub> agonist administration. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal's angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke have been reported with 5-HT<sub>1</sub> agonist administration. Use is contraindicated in patients with a history of stroke or transient ischemic attack</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Headaches: Acute migraine agents (eg, triptans, opioids, ergotamine, or a combination of the agents) used for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasospasm-related events: Peripheral vascular ischemia and colonic ischemia, gastrointestinal ischemia/infarction, splenic infarction, and Raynaud&rsquo;s syndrome have been reported with 5-HT<sub>1</sub> agonist.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Visual effects: Rarely, partial vision loss and blindness (transient and permanent) have been reported with 5-HT<sub>1</sub> agonist.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coronary artery disease: Should not be given to patients who have risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) without adequate cardiac evaluation. Patients with suspected CAD should have cardiovascular evaluation to rule out CAD before considering use; if cardiovascular evaluation is &ldquo;satisfactory,&rdquo; first dose should be given in the healthcare provider's office (consider ECG monitoring). Periodic evaluation of cardiovascular status should be done in all patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; drug clearance may be reduced leading to increased plasma concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in dialysis patients (systemic exposure is increased).</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans) or agents which reduce rizatriptan's metabolism. Concurrent use of serotonin precursors (eg, tryptophan) is not recommended.  If concomitant administration with SSRIs is warranted, monitor closely, especially at initiation and with dose increases.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Maxalt-MLT tablets contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Only indicated for treatment of acute migraine; not for the prevention of migraines or the treatment of cluster headache. If a patient does not respond to the first dose, the diagnosis of migraine should be reconsidered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300011\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218969\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10243&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droxidopa: Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.<b> Exceptions: </b>Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May decrease the metabolism of Serotonin 5-HT1D Receptor Agonists. Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propranolol: May increase the serum concentration of Rizatriptan. Management: Rizatriptan adult dose should be reduced to 5 mg in patients who are also being treated with propranolol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUMAtriptan: Serotonin 5-HT1D Receptor Agonists may enhance the adverse/toxic effect of SUMAtriptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218994\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food delays absorption. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218971\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218982\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. Information related to rizatriptan use in pregnancy is limited (K&auml;ll&eacute;n 2011; Nezvalov&aacute;-Henriksen 2010; Nezvalov&aacute;-Henriksen 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A pregnancy registry has been established to monitor outcomes of women exposed to rizatriptan during pregnancy (800-986-8999). Preliminary data from the pregnancy registry (prospectively collected from 65 live births 1998-2004) does not show an increased risk of congenital malformations (Fiore 2005). Until additional information is available, other agents are preferred for the initial treatment of migraine in pregnancy (Da Silva 2012; MacGregor 2012; Williams 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20548419\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if rizatriptan is excreted in breast milk. The manufacturer recommends that caution be exercised when administering rizatriptan to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218983\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218973\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Headache severity, signs/symptoms suggestive of angina; consider monitoring blood pressure, heart rate, and/or ECG with first dose in patients with likelihood of unrecognized coronary disease, such as patients with significant hypertension, hypercholesterolemia, obese patients, patients with diabetes, smokers with other risk factors or strong family history of coronary artery disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218964\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selective agonist for serotonin (5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors) in cranial arteries; causes vasoconstriction and reduces sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218979\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Exposures following a single dose in pediatric patients &ge;6 years were similar to those observed following a single dose in adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Most patients have response to treatment within 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Females: 110 L; Males 140 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 14%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Via monoamine oxidase-A; forms metabolites; significant first-pass metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~45%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 2-3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Maxalt: 1 to 1.5 hours; Maxalt-MLT: 1.6 to 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (82%, 14% as unchanged drug); feces (12%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218981\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Maxalt-MLT Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (3): $131.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (3): $131.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Rizatriptan Benzoate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (18): $598.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (18): $598.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Maxalt Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $43.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $43.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Rizatriptan Benzoate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (18): $598.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (18): $598.29</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218984\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amigran (BD);</li>\n      <li>maxalt (AE);</li>\n      <li>Maxalt (AR, AT, AU, BB, BE, BG, BR, CH, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HN, HR, HU, IS, IT, KR, KW, LB, LT, LU, MT, MX, NI, NL, NO, NZ, PA, PE, PL, PT, QA, RO, SA, SE, SI, SK, SV);</li>\n      <li>Maxalt RPD (CL, PE, VE);</li>\n      <li>Maxaltlyo (FR);</li>\n      <li>Migoff (TW);</li>\n      <li>Migriz (BD);</li>\n      <li>Migson (IN);</li>\n      <li>Ouliting (CN);</li>\n      <li>Rizact (IN);</li>\n      <li>Rizalt (IL);</li>\n      <li>Rizamelt (NZ);</li>\n      <li>Rizamig (BD);</li>\n      <li>Rizamihren (UA);</li>\n      <li>Rizat (BD);</li>\n      <li>Rizatan (TW);</li>\n      <li>Rizatin (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo; <i>N Engl J Med</i>, 2005, 352(11):1112-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/15784664/pubmed\" target=\"_blank\" id=\"15784664\">15784664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Da Silva AN and Tepper SJ, &quot;Acute Treatment of Migraines,&quot; <i>CNS Drugs</i>, 2012, 26(10):823-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/22823482/pubmed\" target=\"_blank\" id=\"22823482\">22823482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fiore M, Shields KE, Santanello N, et al, &quot;Exposure to Rizatriptan During Pregnancy: Post-Marketing Experience Up to 30 June 2004,&quot; <i>Cephalalgia</i>, 2005, 25(9):685-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/16109049/pubmed\" target=\"_blank\" id=\"16109049\">16109049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&auml;ll&eacute;n B, Nilsson E, and Otterblad Olausson P, &quot;Delivery Outcome After Maternal Use of Drugs for Migraine: A Register Study in Sweden,&quot; <i>Drug Saf</i>, 2011, 34(8):691-703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/21751829/pubmed\" target=\"_blank\" id=\"21751829\">21751829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacGregor EA, &quot;Headache in Pregnancy,&quot; <i>Neurol Clin</i>, 2012, 30(3):835-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/22840792/pubmed\" target=\"_blank\" id=\"22840792\">22840792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maxalt and Maxalt-MLT (rizatriptan) [prescribing information]. Whitehouse Station, NJ: Merck; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maxalt and Maxalt RPD (rizatriptan) [product information]. Kirkland, QC, Canada: Merck Canada Inc; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nezvalov&aacute;-Henriksen K, Spigset O, and Nordeng HM, &quot;Errata in 'Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Sohort Study,'&quot; <i>Headache</i>, 2012, 52(8):1319-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/22946832/pubmed\" target=\"_blank\" id=\"22946832\">22946832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nezvalov&aacute;-Henriksen K, Spigset O, and Nordeng H, &quot;Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Cohort Study,&quot; <i>Headache</i>, 2010, 50(4):563-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/20132339/pubmed\" target=\"_blank\" id=\"20132339\">20132339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams SH and Kehr HA, &quot;An Update in the Treatment of Neurologic Disorders During Pregnancy-Focus on Migraines and Seizures,&quot; <i>J Pharm Pract</i>, 2012, 25(3):341-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/22550159/pubmed\" target=\"_blank\" id=\"22550159\">22550159</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10243 Version 182.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F218997\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F218998\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F219026\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F219001\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F14292543\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F219002\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14292541\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14292542\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F218975\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F218961\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14292544\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F218976\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F218968\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F218980\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F218965\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300011\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F218969\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F218994\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F218971\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F218982\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20548419\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F218983\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F218973\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F218964\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F218979\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F218981\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F218984\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10243|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rizatriptan-patient-drug-information\" class=\"drug drug_patient\">Rizatriptan: Patient drug information</a></li><li><a href=\"topic.htm?path=rizatriptan-pediatric-drug-information\" class=\"drug drug_pediatric\">Rizatriptan: Pediatric drug information</a></li></ul></div></div>","javascript":null}